Racial differences in PSA screening interval and stage at diagnosis

Carpenter, William R.; Howard, Daniel; Taylor, Yhenneko J.; Ross, Lone; Wobker, Sara E.; Godley, Paul A.

doi:10.1007/s10552-010-9535-4

Cited by 67 publications

(62 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A lack of screening may at least to some degree explain the disparities in presentation with high risk disease by race. 23 In regard to treatment although the SEER database captures the type of local therapy, it does not capture some valuable information on men who receive no local treatment. Specifically information on systemic therapy administration is not captured.…”

Section: Discussionmentioning

confidence: 99%

Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This may ameliorate disparities at time of diagnosis that had been present historically. However, it is important to note that in a SEER/Medicare data analysis from 1994 to 2002, there are racial disparities in PSA screening intervals [30] where Blacks, compared to Whites, are more likely to have a longer PSA screening interval prior to prostate cancer diagnosis and a greater likelihood of no pre-cancer diagnosis PSA.…”

Section: Discussionmentioning

confidence: 99%

Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials

Bae

Movsas

et al. 2011

Support Care Cancer

View full text Add to dashboard Cite

Prostate cancer is the most common visceral cancer in men in the USA. The stratification of prostate cancer risk is currently modeled solely on pathologic prognostic factors including PSA and Gleason Score. Independent of these pathologic prognostic factors, our paper describes the central sociodemographic factor of being single as a negative prognostic indicator. Single men are at high risk of poorer outcomes after prostate cancer treatment. Intriguingly, in our group of patients, race was not a significant prognostic factor. The findings in this paper add to the body of work that describes important sociodemographic prognostic factors that are currently underappreciated in patients with cancer. Future steps will include the validation of these findings in prospective studies, and the incorporation of clinical strategies that identify and compensate for sociodemographic factors that predict for poorer cancer outcomes.

show abstract

“…Potential risk factors and prognostic factors can be identified from these data as well [13]. In addition, they might be useful for assessment of trends in the adoption of screening, diagnostic, and treatment procedures, as well as novel technologies [54,56,58,[60][61][62][63][64][65][66][67]. For example, Vickers et al [68] demonstrated that restriction of PSA testing to only young men or selected men aged >70 yr might reduce the risk of overdiagnosis.…”

Section: 4mentioning

confidence: 99%

“…Disparities and variations in the use of imaging and treatment modalities can also be evaluated using diseasespecific registries. In particular, these databases allow examination of the relationship between baseline characteristics and the likelihood of receiving proper staging or adequate treatment [54,56,58,[60][61][62][63][64][65][66][67]. A recent CaPSURE study demonstrated substantial differences in primary treatment between African-American and white men with similar risk profiles [54].…”

Section: 4mentioning

confidence: 99%

“…Comparative effectiveness of open versus robot-assisted RP [78] Impact of primary ADT on survival in men with clinically localized PCa [119] ADT and the risk of cardiovascular diseases, diabetes, fractures, and acute kidney injury in PCa patients [120,121] Racial disparities and geographic variations in primary treatments among PCa patients [64] Increased use of advanced treatment technologies among patients with low-risk PCa and high risk of non-cancer-related mortality [122] Cost implications of the introduction and widespread adoption of advanced treatment technologies for PCa [103] PCOS: Prostate Cancer Outcomes Study Association between age, race, and comorbidity and the probability of receiving a conservative treatment [67] Comparative effectiveness of radical prostatectomy and radiation therapy [37] 15-yr (long-term) disease-specific functional outcomes after RP and radiotherapy [35] …”

Section: 4mentioning

confidence: 99%

See 1 more Smart Citation

Prostate Cancer Registries: Current Status and Future Directions

Gandaglia¹,

Bray

Cooperberg

et al. 2016

European Urology

View full text Add to dashboard Cite

Context: Disease-specific registries that enroll a considerable number of patients play a major role in prostate cancer (PCa) research. Objective: To evaluate available registries, describe their strengths and limitations, and discuss the potential future role of PCa registries in outcomes research. Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms prostate cancer, outcomes, statistical approaches, population-based cohorts, registries of outcomes, and epidemiological studies, alone or in combination. We limited our search to studies published between January 2005 and January 2015. Evidence synthesis: Several population-based and prospective disease-specific registries are currently available for prostate cancer. Studies performed using these data sources provide important information on incidence and mortality, disease characteristics at presentation, risk factors, trends in utilization of health care services, disparities in access to treatment, quality of care, long-term oncologic and health-related quality of life outcomes, and costs associated with management of the disease. Although data from these registries have some limitations, statistical methods are available that can address certain biases and increase the internal and external validity of such analyses. In the future, improvements in data quality, collection of tissue samples, and the availability of data feedback to health care providers will increase the relevance of studies built on population-based and disease-specific registries. Conclusions: The strengths and limitations of PCa registries should be carefully considered when planning studies using these databases. Although randomized controlled trials still provide the highest level of evidence, large registries play an important and growing role in advancing PCa research and care. Patient summary: Several population-based and prospective disease-specific registries for prostate cancer are currently available. Analyses of data from these registries yield information that is clinically relevant for the management of patients with prostate cancer.

show abstract

Racial differences in PSA screening interval and stage at diagnosis

Cited by 67 publications

References 35 publications

Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States

Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States

Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials

Prostate Cancer Registries: Current Status and Future Directions

Contact Info

Product

Resources

About